Published in Proc Natl Acad Sci U S A on January 21, 2009
Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem (2011) 1.27
Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci (2012) 1.21
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett (2010) 1.07
Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe (2011) 1.06
Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog (2012) 1.00
Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol (2013) 0.96
The case of botulinum toxin in milk: experimental data. Appl Environ Microbiol (2010) 0.90
Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol (2014) 0.88
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
Botulinum toxin: bioweapon & magic drug. Indian J Med Res (2010) 0.86
Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Rev Mol Diagn (2014) 0.85
Obstructing toxin pathways by targeted pore blockage. Chem Rev (2012) 0.80
Human Induced Pluripotent Stem Cell Derived Neuronal Cells Cultured on Chemically-Defined Hydrogels for Sensitive In Vitro Detection of Botulinum Neurotoxin. Sci Rep (2015) 0.80
Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One (2015) 0.79
Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions. Neuropharmacology (2010) 0.78
In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5. Toxicon (2015) 0.78
A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins. Sci Rep (2015) 0.78
Cellular Protection of SNAP-25 against Botulinum Neurotoxin/A: Inhibition of Thioredoxin Reductase through a Suicide Substrate Mechanism. J Am Chem Soc (2016) 0.77
Identification of novel host-targeted compounds that protect from anthrax lethal toxin-induced cell death. ACS Chem Biol (2013) 0.77
Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing. Toxins (Basel) (2015) 0.77
Redox regulation of botulinum neurotoxin toxicity: therapeutic implications. Trends Mol Med (2014) 0.77
Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells. Biochem Biophys Res Commun (2012) 0.77
The anti-botulism triterpenoid toosendanin elicits calcium increase and exocytosis in rat sensory neurons. Cell Mol Neurobiol (2011) 0.76
Antigen detection via the rate of ion current rectification change of the antibody-modified glass nanopore membrane. Langmuir (2014) 0.76
A high content imaging assay for identification of Botulinum neurotoxin inhibitors. J Vis Exp (2014) 0.76
SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. Neurotox Res (2015) 0.76
Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays. PLoS One (2015) 0.75
A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action. Chem Commun (Camb) (2011) 0.75
Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep (2015) 0.75
Toosendanin: synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II). Bioorg Med Chem (2009) 0.75
Inhibiting Microbial Toxins Using Plant-Derived Compounds and Plant Extracts. Medicines (Basel) (2015) 0.75
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Neurotoxins affecting neuroexocytosis. Physiol Rev (2000) 5.42
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol (1998) 4.21
Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol (2004) 3.69
Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol (2000) 3.31
Substrate recognition strategy for botulinum neurotoxin serotype A. Nature (2004) 2.81
Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature (2006) 2.20
Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol (2003) 2.19
The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett (2006) 2.04
Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (2006) 1.97
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis (1984) 1.82
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 1.79
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem (2004) 1.67
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell (2008) 1.66
Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A (2007) 1.59
Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci (2005) 1.49
Purification of Clostridium botulinum type A neurotoxin. Methods Mol Biol (2000) 1.47
Uptake of botulinum neurotoxin into cultured neurons. Biochemistry (2004) 1.43
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett (2007) 1.40
Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem (2007) 1.39
Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem (2007) 1.30
Carboxylesterases--detoxifying enzymes and targets for drug therapy. Curr Med Chem (2006) 1.19
Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem (2008) 1.08
Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc Natl Acad Sci U S A (2004) 1.08
Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry (2005) 1.02
Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212-->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry (2004) 1.00
Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry (2005) 1.00
Characterization of Clostridial botulinum neurotoxin channels in neuroblastoma cells. Neurotox Res (2006) 0.93
Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B. Acta Crystallogr D Biol Crystallogr (2001) 0.89
The effect of toosendanin on monkey botulism. J Tradit Chin Med (1985) 0.89
Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog Neurobiol (2007) 0.88
Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol Sin (2004) 0.83
Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett (2003) 0.81
Investigations of mechanisms of reactive metabolite formation from (R)-(+)-pulegone. Xenobiotica (1992) 0.77
Rapid SNP discovery and genetic mapping using sequenced RAD markers. PLoS One (2008) 13.64
Population genomics of parallel adaptation in threespine stickleback using sequenced RAD tags. PLoS Genet (2010) 7.05
The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood) (2010) 6.60
Rapid and cost-effective polymorphism identification and genotyping using restriction site associated DNA (RAD) markers. Genome Res (2006) 5.80
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Piezo proteins are pore-forming subunits of mechanically activated channels. Nature (2012) 3.54
Construction and application for QTL analysis of a Restriction Site Associated DNA (RAD) linkage map in barley. BMC Genomics (2011) 3.42
Single-cell microbiology: tools, technologies, and applications. Microbiol Mol Biol Rev (2004) 2.53
Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science (2002) 2.51
A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J Neurosci (2004) 2.31
Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol (2007) 2.24
Evidence for ozone formation in human atherosclerotic arteries. Science (2003) 2.22
Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol (2003) 2.19
RAD marker microarrays enable rapid mapping of zebrafish mutations. Genome Biol (2007) 2.07
Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proc Natl Acad Sci U S A (2004) 2.05
Three-dimensional structure of the channel-forming trans-membrane domain of virus protein "u" (Vpu) from HIV-1. J Mol Biol (2003) 1.99
Local de novo assembly of RAD paired-end contigs using short sequencing reads. PLoS One (2011) 1.98
Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (2006) 1.97
SNP discovery and genotyping for evolutionary genetics using RAD sequencing. Methods Mol Biol (2011) 1.96
Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. Science (2008) 1.93
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr Microbiol (2003) 1.83
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol (2003) 1.81
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex. Science (2008) 1.79
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
High-density detection of restriction-site-associated DNA markers for rapid mapping of mutated loci in Neurospora. Genetics (2007) 1.78
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Treating cocaine addiction with viruses. Proc Natl Acad Sci U S A (2004) 1.75
Structure of the Escherichia coli quorum sensing protein SdiA: activation of the folding switch by acyl homoserine lactones. J Mol Biol (2005) 1.74
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell (2008) 1.66
Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl Environ Microbiol (2008) 1.62
Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A (2007) 1.59
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend (2012) 1.57
Uncharacterized 4,5-dihydroxy-2,3-pentanedione (DPD) molecules revealed through NMR spectroscopy: implications for a greater signaling diversity in bacterial species. Angew Chem Int Ed Engl (2012) 1.55
Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci (2002) 1.54
Phylogenetic analysis of Clostridium botulinum type A by multi-locus sequence typing. Microbiology (2008) 1.52
Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. Biochem Biophys Res Commun (2007) 1.52
Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc (2005) 1.48
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry (2006) 1.48
A vaccine strategy that induces protective immunity against heroin. J Med Chem (2011) 1.47
Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob Agents Chemother (2003) 1.47
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif (2004) 1.45
Vaccination against weight gain. Proc Natl Acad Sci U S A (2006) 1.45
Genetic homogeneity of Clostridium botulinum type A1 strains with unique toxin gene clusters. Appl Environ Microbiol (2008) 1.44
Nav1.1 channels with mutations of severe myoclonic epilepsy in infancy display attenuated currents. Epilepsy Res (2003) 1.42
N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. J Biol Chem (2006) 1.42
Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci U S A (2004) 1.40
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett (2007) 1.40
Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav (2009) 1.39
MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav (2007) 1.39
Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem (2007) 1.39
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem (2004) 1.37
Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm (2007) 1.35
Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem (2002) 1.33
Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc (2011) 1.31
Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916. Anaerobe (2004) 1.30
Synthesis and biological validation of a ubiquitous quorum-sensing molecule. Angew Chem Int Ed Engl (2004) 1.29
Molecular and pathological effects of a modifier gene on deficiency of the sodium channel Scn8a (Na(v)1.6). Hum Mol Genet (2002) 1.29
Bleeding stomal varices: case series and systematic review of the literature. Clin Gastroenterol Hepatol (2008) 1.29
Safety of using a computerized rounding and sign-out system to reduce resident duty hours. Acad Med (2010) 1.29
Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog (2007) 1.28
Identification of a lycopene beta-cyclase required for bacteriorhodopsin biogenesis in the archaeon Halobacterium salinarum. J Bacteriol (2002) 1.28
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol (2006) 1.26
Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol (2013) 1.26
A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm (2010) 1.26
Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol Lett (2004) 1.25
Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One (2012) 1.25
Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb) (2006) 1.25
Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A (2013) 1.24
Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog (2011) 1.24
Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog (2008) 1.23
Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods (2010) 1.21
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc Natl Acad Sci U S A (2004) 1.21
Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci (2012) 1.21